Alluvi, formerly BI 4744, represents a promising breakthrough in obesity therapy. This dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates impressive https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/